Welcome to our dedicated page for Alignment Healthcare SEC filings (Ticker: ALHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Alignment Healthcare, Inc.'s SEC filings document a Medicare Advantage operating company with common stock listed on Nasdaq under ALHC. Its Form 8-K reports furnish quarterly and annual operating results, health plan membership, revenue, adjusted gross profit, adjusted EBITDA, guidance updates and Regulation FD materials related to strategy, market position and Medicare Advantage quality ratings.
Proxy materials cover board elections, executive compensation, equity awards, pay-versus-performance data and shareholder voting matters. Registration statements, prospectus supplements and underwriting agreements describe secondary offerings of common stock by selling stockholders, the company's capital structure and related securities-law obligations.
A group of reporting persons led by General Atlantic (ALN HLTH), L.P., which is identified as a director and 10% owner of Alignment Healthcare, Inc., reported a large open-market sale of the company’s common stock. On December 12, 2025, they sold 11,119,494 shares of common stock at a net price of $18.57 per share.
After this transaction, the group reports indirect beneficial ownership of 13,476,585 Alignment Healthcare shares. This includes 13,167,733 shares held directly by General Atlantic (ALN HLTH), L.P., plus additional shares and 18,710 restricted stock units for each of Nicholas Robbert Vorhoff and David C. Hodgson held for the benefit of General Atlantic Service Company, L.P. The reporting persons describe a multi-entity General Atlantic structure and state that each disclaims beneficial ownership beyond any pecuniary interest.
Alignment Healthcare, Inc. reported an insider transaction by Sebastian Burzacchi, its chief operating officer for the management services organization. On 12/10/2025, he sold 12,585 shares of Alignment Healthcare common stock at $19.26 per share. According to the explanation, this represents the number of shares required to be sold to cover tax withholding obligations in connection with the vesting of restricted stock units and does not represent a discretionary trade by the reporting person. After the sale, he beneficially owns 237,793 shares of Alignment Healthcare common stock held directly.
Alignment Healthcare, Inc. disclosed that Chief Executive Officer and director John E. Kao sold 180,000 shares of common stock on 12/10/2025. The sale was reported at a weighted-average price of $19.0179 per share, with individual trades executed between $18.84 and $19.46 under a Rule 10b5-1 trading plan adopted on 03/12/2025.
Following this transaction, Kao beneficially owns 2,346,726 shares indirectly through the JEK Trust, for which he serves as trustee, and 2,839,942 shares directly.
Alignment Healthcare (ALHC) reported an insider transaction by Director Joseph S. Konowiecki. On 11/11/2025, 4,832 shares of common stock were sold at $16.49. The filing states the sale was to satisfy tax withholding from the vesting of restricted stock units and was not a discretionary trade by the reporting person.
Following the transaction, the director beneficially owns 1,081,141 shares, held directly.
Alignment Healthcare (ALHC) — insider transaction: CEO and director John E. Kao, via the JEK Trust, sold 180,000 shares of common stock on 11/10/2025 at a weighted-average price of $16.3154. The sale was made under a Rule 10b5-1 trading plan adopted on 03/12/2025.
After the transaction, Mr. Kao beneficially owns 2,526,726 shares indirectly through the JEK Trust and 2,839,942 shares directly.
Alignment Healthcare (ALHC) reported Q3 2025 results showing strong top-line growth and a return to profitability. Revenue rose to $993.7 million from $692.4 million a year ago, driven by earned premiums of $983.7 million. Medical expenses were $868.0 million and SG&A was $110.0 million, yielding operating income of $7.7 million.
Net income was $3.7 million versus a $26.4 million loss last year, with diluted EPS of $0.02. Year-to-date, revenue reached $2.94 billion and net income was $10.0 million. Cash and cash equivalents were $618.1 million as of September 30, 2025, supported by $190.3 million of net cash provided by operating activities year-to-date. Long-term debt stood at $322.7 million (carrying value) tied to 4.25% convertible senior notes due 2029. Medical expenses payable increased to $528.8 million from $289.8 million at December 31, 2024. Shares outstanding were 199,988,515 as of September 30, 2025; as of October 27, 2025, they were 200,091,742.
Alignment Healthcare, Inc. furnished a Form 8-K to announce it issued a press release with financial results for its third quarter ended September 30, 2025. The press release is included as Exhibit 99.1.
The information under Item 2.02 and Exhibit 99.1 is furnished, not filed, and is not subject to Section 18 of the Exchange Act, nor incorporated by reference into other filings unless expressly stated.
Alignment Healthcare (ALHC) director reports an open‑market sale. Joseph S. Konowiecki sold 25,000 shares of common stock on 10/28/2025 at a price of $18 per share (transaction code S(1)). Following the sale, he beneficially owns 1,085,973 shares, held directly.
The footnote indicates a Rule 10b5‑1 trading plan adopted on 03/05/2025 in connection with the sale. No derivative securities transactions were reported in this filing.
Alignment Healthcare (ALHC) CEO and director John E. Kao reported the sale of 180,000 shares of common stock on 10/10/2025 under a Rule 10b5-1 trading plan adopted on 03/12/2025.
The weighted-average sale price was $17.286, with individual trades ranging from $16.97 to $17.60. Following the transaction, beneficial ownership included 2,706,726 shares held indirectly by the JEK Trust and 2,839,942 shares held directly. A prior transfer on 09/25/2025 moved 1,693,626 shares from direct ownership to the JEK Trust.
Alignment Healthcare (ALHC) Chief Medical Officer Hyong (Ken) Kim reported two non-discretionary stock sales tied to restricted stock unit vesting and a pre-existing trading plan. On 10/08/2025 Mr. Kim sold 33,655 shares at $17.29 to cover tax withholding, leaving 413,712 shares prior to the second sale. On 10/09/2025 he sold 51,379 shares at $17.5713, leaving 362,333 shares beneficially owned after the transactions. The Form 4 notes a Rule 10b5-1 trading plan adopted on 03/14/2025, and the filings state these sales were not discretionary trades but routine tax-withholding dispositions tied to RSU vesting.